Working Group: Restructure NCI, Improve Review Process, Encourage Independence
In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb
“Significant changes should be made to reduce redundancy, streamline operations, promote collaboration, and optimize productivity.”
“Perhaps the most troubling finding was a broad dissatisfaction with the general ethos within the intramural community.”
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
